Dextropropoxyphene — marketed historically as propoxyphene — is an opioid analgesic that was withdrawn from the US market by FDA in 2010 due to cardiac safety concerns, meaning current imports under this heading (2922140000) are almost exclusively for research, reference standard, or export-manufacturing purposes rather than domestic pharmaceutical use. As a DEA Schedule IV controlled substance, any importation requires a DEA import permit and strict chain-of-custody documentation. Switzerland is the sole identified supplier in current US trade data, consistent with the compound's niche role as a reference standard or intermediate in Swiss fine-chemical production. Importers must coordinate DEA, FDA, and CBP requirements simultaneously, as the compound's withdrawn-drug status adds a layer of regulatory complexity beyond standard controlled-substance procedures.

AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.